SMS Pharmaceuticals per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹11.24₹11.15₹8.16₹5.89−₹0.83
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹11.24₹11.15₹8.16₹5.89₹0.00
₹83.91₹83.91₹72.15₹63.36₹54.40
₹95.86₹94.70₹88.29₹83.79₹61.67
—₹6.32₹9.22₹5.92₹2.65
−₹7.62−₹7.62−₹4.70−₹0.24−₹0.88
—₹0.38₹0.38₹0.30₹0.30
9.49.48.98.58.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABSOLARADCALUNICHEMLABGUFICBIORPGLIFEHIKALGUJTHEMMcap ₹4,453 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-0.835.898.1611.1511.24
Diluted EPS0.005.898.1611.1511.24
Book Value per Share54.4063.3672.1583.9183.91
Revenue per Share61.6783.7988.2994.7095.86
Cash Flow per Share2.655.929.226.32—
Free Cash Flow per Share-0.88-0.24-4.70-7.62-7.62
Dividends per Share0.300.300.380.38—
Shares Outstanding (cr)8.58.58.99.49.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.